Ozmosi | Eflornithine Drug Profile
Drug Search Results
Using advanced filters...
Advanced Search [+]

Eflornithine

Alternative Names: eflornithine, difluoromethylornithine, vaniqa, ornidyl, IWILFIN
Clinical Status: Inactive
Latest Update: 2026-02-04
Latest Update Note: News Article

Product Description

Eflornithine administered by injection is used to treat African sleeping sickness, a disease caused by protozoa (tiny one-celled animals). However, eflornithine hydrochloride applied topically as a cream is the first agent known to help slow the rate of excessive hair growth. It is marketed under the brand name Vaniqa® and comes as eflornithine hydrochloride 13.9% cream. Eflornithine works by blocking the enzyme ornithine decarboxylase (ODC) that stimulates hair growth. (Sourced from: https://dermnetnz.org/topics/eflornithine-hydrochloride)

Mechanisms of Action: ODC Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: *

Approval Status: Approved

Approved Countries: Austria | Bangladesh | Belgium | Brazil | Canada | Chile | Croatia | Czech | Denmark | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hungary | Iceland | India | Ireland | Israel | Italy | Jordan | Latvia | Lebanon | Lithuania | Netherlands | New Zealand | Norway | Pakistan | Peru | Poland | Portugal | Romania | Slovakia | Spain | Sweden | Switzerland | Turkey | United Kingdom | United States

Approved Indications: None

Known Adverse Events: None

Company: Takeda
Company Location: Asia Pacific
Company Founding Year: 1781
Additional Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Eflornithine

Countries in Clinic: United States

Active Clinical Trial Count: 5

Recent & Upcoming Milestones

Highest Development Phases

Phase 3: Astrocytoma

Phase 2: Breast Cancer|Melanoma|Neuroblastoma|Prostate Cancer|Skin Cancer

Phase 1: Glioblastoma

Trial ID

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Latest Trial Update Date

Data Updated

NCT05879367

OT-21-101

P1

Recruiting

Astrocytoma|Glioblastoma

2026-06-30

50%

2025-06-26

Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments

NCT07287917

AMXT1501-103

P2

Recruiting

Skin Cancer|Melanoma|Breast Cancer

2028-02-28

12%

2025-12-18

Primary Endpoints|Treatments

NCT06059118

J2326

P2

Recruiting

Prostate Cancer

2027-01-04

12%

2026-01-15

Primary Completion Date|Primary Endpoints|Treatments

NCT02139397

NMTRC010

P2

Completed

Neuroblastoma

2024-01-19

30%

2024-04-26

Primary Completion Date|Primary Endpoints|Start Date|Study Completion Date|Treatments|Trial Status

2016-000089-45

STELLAR Study

P3

Completed

Astrocytoma

2024-02-27

2025-07-09

Treatments